First Tracks Biotherapeutics (NASDAQ:TRAX) Short Interest Update

First Tracks Biotherapeutics (NASDAQ:TRAX) saw a significant increase in short interest in April. As of April 30th, there was short interest totaling 4,029,808 shares, an increase of ∞ from the April 15th total of 0 shares. Based on an average trading volume of 537,279 shares, the days-to-cover ratio is currently 7.5 days.

Analysts Set New Price Targets

A number of analysts have recently issued reports on TRAX shares. UBS Group started coverage on First Tracks Biotherapeutics in a research note on Tuesday, April 21st. They issued a “buy” rating and a $45.00 price target on the stock. Piper Sandler started coverage on First Tracks Biotherapeutics in a research note on Monday, May 4th. They issued an “overweight” rating and a $54.00 price target on the stock. Zacks Research raised First Tracks Biotherapeutics to a “hold” rating in a research note on Monday, April 27th. JPMorgan Chase & Co. started coverage on First Tracks Biotherapeutics in a research note on Thursday, April 23rd. They issued an “overweight” rating and a $31.00 price target on the stock. Finally, Barclays assumed coverage on First Tracks Biotherapeutics in a research note on Wednesday, April 22nd. They issued an “overweight” rating and a $40.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $39.43.

First Tracks Biotherapeutics Stock Performance

Shares of NASDAQ TRAX traded up $0.97 during midday trading on Monday, reaching $17.87. 182,994 shares of the stock were exchanged, compared to its average volume of 399,532. First Tracks Biotherapeutics has a twelve month low of $14.79 and a twelve month high of $26.80.